Survey: Monthly Opioid Treatment Shot Reduces Misuse in Correctional Facilities, Positive for Indivior
INDV has more than doubled off its 52-week low of $8.69 on light trading volume (0.2× avg).
Summary
Indivior announced results from a national survey indicating that correctional facility staff believe long-acting injectable (LAI) buprenorphine, a treatment for opioid use disorder, can significantly reduce medication misuse. A strong majority (88% of jail staff and 87% of prison staff) reported that LAI buprenorphine could help mitigate diversion within their facilities. This positive market perception data supports the potential for increased adoption of Indivior's key products, such as Sublocade, in the correctional system, addressing a critical concern regarding medication diversion. While cost and access remain barriers, these findings reinforce the value proposition of Indivior's offerings in a challenging but significant market segment. Investors should monitor future policy changes and funding initiatives that could facilitate broader implementation of such treatments in correctional settings.
At the time of this announcement, INDV was trading at $31.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $8.69 to $38.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.